Pretreatment HDL‐C and ApoA1 are predictive biomarkers of progression‐free survival in patients with EGFR mutated advanced non‐small cell lung cancer treated with TKI

Abstract Background We aimed to explore the correlation between blood lipids (high density lipoprotein cholesterol [HDL‐C] and apolipoprotein A1 [ApoA1]) and epidermal growth factor receptor (EGFR) T790M mutation, as well as its predictive role in clinical efficacy and progression‐free survial (PFS)...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Juan Ma, Ying Bai, Mei Liu, Tong Jiao, Yang Chen, Bo Yuan, Boxuan Liu, Lizhong Zeng, Zongjuan Ming, Wei Li, Ruiying Sun, Xia Yang, Shuanying Yang
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2022-04-01
Rangatū:	Thoracic Cancer
Ngā marau:	advanced non‐small cell lung cancer apolipoprotein A1 epidermal growth factor receptor high density lipoprotein cholesterol progression‐free survival
Urunga tuihono:	https://doi.org/10.1111/1759-7714.14367
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!